Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study
STOCKHOLM, June 25, 2020 /PRNewswire/ --Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox.
- STOCKHOLM, June 25, 2020 /PRNewswire/ --Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox.
- The pattern is consistent with the results from the North American Phase 3 study, with low complete cure rates despite the high mycological cure rates.
- The primary endpoint was met in both studies, the proportion of patients achieving complete cure of their target nail.
- This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.